BOTHELL, Wash. / Apr 05, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present... Read More

Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 BOTHELL, Wash. / Mar 28, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the... Read More

BOTHELL, Wash. / Mar 26, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the successful completion of its purchase of AL102 and related drug candidate AL101 from Ayala Pharmaceuticals, Inc. “AL102 is a high-quality asset that complements our existing pipeline of targeted cancer therapies,” said Clay... Read More

BOTHELL, Wash. / Mar 07, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, Ph.D., President and CEO of Immunome, will present at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12, 2024 at 4:20 p.m. ET. Interested parties can access the live audio webcast for... Read More

BOTHELL, Wash. / Mar 01, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50 p.m. ET. Interested parties can access... Read More

Immunome entered into a definitive asset purchase agreement with Ayala to acquire AL102 earlier this month BOTHELL, Wash. / Feb 20, 2024 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today recognized the announcement by Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, that patient... Read More

BOTHELL, Wash. / Feb 16, 2024 / Business Wire / Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 10,000,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,500,000 shares, at a price... Read More

BOTHELL, Wash. / Feb 13, 2024 / Business Wire / Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share. All of the shares are to be sold by Immunome. The gross proceeds to Immunome... Read More

BOTHELL, Wash. / Feb 13, 2024 / Business Wire / Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its common stock. All of the shares are being offered by Immunome. In... Read More

BOTHELL, Wash. / Feb 05, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome management will present at the Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference on Thursday, February 8 at 9:30 a.m. ET. Interested parties can access the live audio webcast for this... Read More

Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025 Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and is eligible to receive up to $275 million of milestone payments and mid-to-high single-digit royalties BOTHELL, Wash. & SAN DIEGO & NEW YORK / Jan 08,... Read More

BOTHELL, Wash. / Jan 04, 2024 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Phil Roberts as Chief Technical Officer. Mr. Roberts has over three decades of experience in product development, global manufacturing, and commercialization of novel pharmaceutical products. “Immunome is... Read More

BOTHELL, Wash. / Jan 03, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Thursday, January 8 at 7:30 a.m. PT. Interested parties can access the live audio webcast for this... Read More

BOTHELL, Wash. & EXTON, Pa. / Jan 02, 2024 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Carol A. Schafer to its Board of Directors. Ms. Schafer has more than 25 years of experience in investment banking and equity capital markets and has served as a corporate director for multiple... Read More

SEATTLE & EXTON, Pa. / Dec 26, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Atreca, Inc. (Nasdaq: BCEL) to acquire a collection of antibody-related assets and materials. “We believe that novel and underexplored targets will drive the... Read More

SEATTLE & EXTON, Pa. / Nov 10, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET. Interested parties can access the live audio webcast for this... Read More

Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO Bob Lechleider, M.D., appointed as Chief Medical Officer Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors Cash runway expected to extend into Q1 2026* SEATTLE &... Read More

Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors SEATTLE & EXTON, Pa. / Nov 08, 2023 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors. Mr. Bienaimé... Read More

Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies SEATTLE & EXTON, Pa. / Oct 19, 2023 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Bob Lechleider, M.D., as Chief Medical... Read More

Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026* Expected to submit three investigational new drug applications (INDs) within 18 months SEATTLE & EXTON, Pa. / Oct 03, 2023 / Business Wire / Immunome , Inc. (Nasdaq: IMNM), a... Read More

EXTON, Pa. / Aug 09, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update. “We believe combining Immunome and Morphimmune’s technologies represents a major... Read More

The combined company, which will operate as Immunome, will feature a synergistic platform expected to enable the development of best-in-class targeted cancer therapies across multiple modalities Clay B. Siegall , Ph.D., current Morphimmune President & CEO and former co-founder & CEO of Seagen, Inc., to serve as Chairman and CEO of combined company A concurrent $125 million private placement investment with leading... Read More

EXTON, Pa. / May 23, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled “ IL-38 blockade induces anti-tumor immunity by abrogating tumor-mediated suppression of... Read More

EXTON, Pa. / May 05, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update. “The external validation of our Discovery Engine through our collaboration with... Read More

EXTON, Pa. / Mar 09, 2023 / Business Wire / Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop antibody therapeutics to improve patient care, today announced that Matthew Robinson, Ph.D., Chief Technology Officer, will present at the 13 th Annual World ADC London conference, taking place from March 13-16, 2023. World ADC London is Europe’s longest... Read More